Skip to content

Dual antiplatelet therapy beyond 12 months versus for 12 months after drug-eluting stents for acute myocardial infarction

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q3Scopus Q1
Journal
JOURNAL OF CARDIOLOGY75(1) · pp.66 · 2020
Citation
Web of Science 9Scopus 11
FWCI (Scopus)
0
JCR IF
JCR 2019 2.246
ISSN
0914-5087

Authors

  1. Sim, Doo SunFirst authorChonnam National University Hospital, Gwanjgu, Republic of Korea
  2. Jeong, Myung HoCorresponding authorChonnam National University Hospital, Gwanjgu, Republic of Korea
  3. Kim, Hyo SooSeoul National University Hospital, Seoul, Republic of Korea
  4. Gwon, Hyeon CheolSungkyunkwan University, Seoul Samsung Medical Center, Seoul, Republic of Korea
  5. Seung, Ki BaeThe Catholic University of Korea, Seoul, Republic of Korea
  6. Rha, Seung WoonKorea University Guro Hospital, Seoul, Republic of Korea
  7. Chae, Shung ChullKyungpook National University Hospital, Daegu, Republic of Korea
  8. Kim, Chong JinKyung Hee University Hospital at Gangdong, Seoul, Republic of Korea
  9. Cha, Kwang-sooPusan National University Hospital, Busan, Republic of Korea
  10. Park, Jong SeonYeungnam University Hospital, Daegu, Republic of Korea
  11. Yoon, Jung HanYonsei University Wonju College of Medicine, Wonju Severance Christian Hospital, Wonju, Republic of Korea
  12. Chae, Jei KeonChunbuk National University Hospital, Jeonju, Republic of Korea
  13. Joo, Seung JaeJeju National University Hospital, Jeju, Republic of Korea
  14. Choi, Dong JuSeoul National University Bundang Hospital, Seongnam, Republic of Korea
  15. Hur, Seung HoKeimyung University Dongsan Medical Center, Daegu, Republic of Korea
  16. Seong, In WhanChungnam National University Hospital, Daejeon, Republic of Korea
  17. Cho, Myeong ChanChungbuk National University Hospital, Cheongju, Republic of Korea
  18. Kim, Doo IlInje University Haeundae Paik Hospital, Busan, Republic of Korea
  19. Oh, Seok KyuWonkwang University Hospital, Iksan, Republic of Korea
  20. Ahn, Tae HoonGachon University Gil Medical Center, Incheon, Republic of Korea
  21. Hwang, Jin YongKyungsang National University Hospital, Jinju, Republic of Korea

Abstract

Background: The optimal duration of dual antiplatelet therapy (DAPT) after acute coronary syndrome remains uncertain. This study investigated the benefit of DAPT beyond 12 months after drug-eluting stents (DES) for acute myocardial infarction (MI). Methods: From Korea Acute Myocardial Infarction Registry-National Institute of Health database, 6199 patients treated with DAPT for 12 months after DES (second-generation DES 98%) without ischemic or bleeding events were analyzed. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), a composite of death from any cause, MI, or ischemic stroke during the period from 12 to 24 months. Results: After adjustment using inverse probability of treatment weighting, patients who received DAPT beyond 12 months (n = 4795), compared to patients treated with 12-month DAPT (n = 1404), had a similar incidence of MACCE (1.3% vs. 1.0%, HR: 1.32, 95% CI: 0.71-2.45, p = 0.378). The 2 groups did not differ significantly in the rates of death (0.1% vs. 0.1%), MI (0.8% vs.0.6%), stent thrombosis (0.1% vs. 0.2%), ischemic stroke (0.4% vs. 0.2%), and major bleeding (0.1% vs. 0.1%). The rate of net adverse clinical events was 1.4% with DAPT beyond 12 months and 1.1% with 12-month DAPT (p = 0.466). Conclusions: DAPT beyond 12 months, as compared with 12-month DAPT, in real-world patients with acute MI treated predominantly with second-generation DES did not reduce the risk of MACCE. The rates of major bleeding and net adverse clinical events did not differ significantly between the 2 treatments. (C) 2019 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Keywords

Antiplatelet agentsDrug-eluting stentsMyocardial infarctionFOCUSED UPDATEIMPLANTATIONCLOPIDOGRELDURATIONTRIALMETAANALYSISVALIDATIONTICAGRELORGUIDELINEEFFICACY

Identifiers

Scopus EID
2-s2.0-85072586455
WoS UID
000527373800011